Loading
Pelthos Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 Jun 2026.
Pelthos Therapeutics Inc.: what insiders have been doing
Pelthos Therapeutics Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 10 insiders have disclosed 37 filings since 18 October 2025.
On the market, 1 insider bought (2 purchases) while 4 insiders sold (18 sales totalling €284k). The amount is not disclosed for 2 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 senior executive. Biggest ticket of the year: €146k, sold by Friedberg Ezra M and made public on 26 November 2025.
The last insider purchase was made public on 15 June 2026, 125 days ago. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 37 filings here. Our records for Pelthos Therapeutics Inc. go back to 2024, with 6 purchases and 18 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
48
Thresholds
n/a
Buy Volume
€108,088
6 ops. · all time
Sell Volume
€284,265
18 ops. · all time
Who traded when
BuySaleEzra M. Friedberg6 sales
Matthew Pauls5 sales
Peter Greenleaf5 sales
Richard Malamut2 sales
Todd C. Davis2 buys
Since the insiders bought
- -27.7%Entry US$28.02 · Close 16 Oct 2026 US$20.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Pelthos Therapeutics Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$51.71.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$20.25
Analyst consensus
7 analystsStrong buy
US$40.00Target US$51.71(+155%)US$64.00
Income statement
RevenueUS$16.8M
Gross profitUS$7.4M44% margin
EBITDA-US$45.4M-270% margin
Net income-US$43.3M-199.5% margin
Valuation
PER (forward)-3.9x
P/Book2.5x
Beta3.11
Balance sheet & cash
Market capUS$77.5M
Total debtUS$34.8M
Free Cash Flow-US$30.6M
Debt / Equity151%
Profitability & ownership
ROE-333.8%
ROA-50.0%
% insiders50.0%
% institutions42.3%
Last declaration on 6 October 2026
Declarations48 total
797 shares@ US$21.170.021% mcap31.5% of flowCommon StockSEC:0001919246-26-000131:0
558 shares@ US$20.71690.015% mcap2.0% of flowCommon StockSEC:0001919246-26-000130:0
786 shares@ US$21.000.021% mcap31.3% of flowCommon StockSEC:0001919246-26-000129:0
534 shares@ US$26.03030.015% mcap2.4% of flowCommon StockSEC:0001919246-26-000102:0
24 shares@ US$27.32540.0007% mcap0.1% of flowCommon StockSEC:0001919246-26-000102:1
692 shares@ US$25.99590.020% mcap48.8% of flowCommon StockSEC:0001919246-26-000101:0
94 shares@ US$27.36040.0028% mcap7.0% of flowCommon StockSEC:0001919246-26-000101:1
712 shares@ US$25.99540.020% mcap49.6% of flowCommon StockSEC:0001919246-26-000100:0
85 shares@ US$27.27330.0026% mcap6.2% of flowCommon StockSEC:0001919246-26-000100:1
35,445 sharesCommon StockSEC:0001919246-26-000088:0
Canonical exit: 9 Sept 2026 (T+90)
503 sharesCommon StockSEC:0001919246-26-000088:1
Canonical exit: 9 Sept 2026 (T+90)
293 shares@ US$20.51211.0% of flowCommon StockSEC:0001919246-26-000054:0
310 shares@ US$20.512651.5% of flowCommon StockSEC:0001919246-26-000055:0
280 shares@ US$21.361248.5% of flowCommon StockSEC:0001919246-26-000055:1
415 shares@ US$20.515422.9% of flowCommon StockSEC:0001919246-26-000053:0
371 shares@ US$21.362821.3% of flowCommon StockSEC:0001919246-26-000053:1
265 shares@ US$21.36121.0% of flowCommon StockSEC:0001919246-26-000054:1
420 shares@ US$20.515122.8% of flowCommon StockSEC:0001919246-26-000052:0
377 shares@ US$21.361421.4% of flowCommon StockSEC:0001919246-26-000052:1
33,472 shares0Common StockSEC:0001919246-26-000039:0
4,961 shares0Common StockSEC:0001919246-26-000046:1
6,450 shares0Common StockSEC:0001919246-26-000047:0
2,454 shares0Common StockSEC:0001919246-26-000047:1
19,108 shares0Common StockSEC:0001919246-26-000047:2
6,450 shares0Common StockSEC:0001919246-26-000045:0
25 of 48 declarations
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. (ticker: PTHS) is a U.S.-based biopharmaceutical company listed on NYSE American in the United States, with a focused strategy centered on commercializing differentiated dermatology-oriented therapeutic products. The company’s current identity reflects a strategic transformation completed in 2025, including a name change from Channel Therapeutics Corporation, which underscores a shift toward a more commercial biopharma model rather than a legacy development-stage structure. Pelthos is headquartered in Durham, North Carolina, and its disclosed facility there serves both as corporate headquarters and as the company’s primary manufacturing site for berdazimer sodium API used in ZELSUVMI. Its public filings emphasize a mission to address unmet treatment burdens through innovative, safe, and effective products.
The company’s near-term investment story is built around ZELSUVMI™ (berdazimer) topical gel, 10.3%, which Pelthos identifies as its lead product. The asset is positioned as a differentiated prescription topical therapy for a contagious viral skin condition, with the notable convenience of being usable at home by patients, parents, or caregivers rather than only in a physician’s office or similar medical setting. That at-home administration profile is an important commercial differentiator and potentially supports broader access and ease of adoption. From an equity analyst perspective, Pelthos therefore represents a concentrated commercial-stage biotechnology case: upside is tied to one flagship product and its market penetration, while execution risk remains elevated because of the company’s limited diversification.
Read moreShow less
Historically, Pelthos’ current form emerged from a restructuring and transaction-driven repositioning in 2025, including the reverse stock split and the conversion into a NYSE American-listed issuer under the PTHS symbol. The company’s recent corporate history also includes an acquisition-related transition and the launch of Pelthos as a standalone biopharmaceutical platform. That background matters because it signals that management is still in the early phases of building the operating model, the commercial infrastructure, and the revenue base. In other words, the investment thesis is less about a mature product portfolio and more about the successful ramp of a niche specialty asset.
Competitively, Pelthos operates in a specialized segment of dermatology/infectious skin disease where clinical differentiation, usability, and physician acceptance matter more than scale alone. It is much smaller than large U.S. pharmaceutical peers, but the company aims to carve out a defensible position through product specificity and a lean cost structure. Recent public disclosures in 2026 show continued SEC activity and corporate updates, reflecting an issuer that remains in build-out mode and under close investor scrutiny. For investors in France, Belgium, and Switzerland, Pelthos should be viewed as a U.S. small-cap health and pharma name with a high-variance profile: meaningful product-driven optionality, but also meaningful dependence on execution, manufacturing consistency, and market uptake of ZELSUVMI.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
